MyFinsight
Home
Blog
About
Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$39,629K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net product revenue
Other liabilities
Proceeds from maturities and sal...
Others
Negative Cash Flow Breakdown
Purchase of investment securitie...
Cost of product sold
Research and development
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net product revenue
261,280
215,387
243,776
239,455
Cost of product sold
63,191
44,505
68,538
59,643
Research and development
44,034
35,018
41,935
37,704
Sales and marketing
32,311
29,899
27,693
28,055
General and administrative
16,884
20,398
45,079
16,774
Depreciation and amortization
5,968
5,968
7,432
5,968
Stock-based compensation
9,576
10,308
10,292
10,824
Interest expense
3,070
3,234
3,546
3,621
Interest income
7,072
5,757
5,854
26,410
Income tax expense
17,834
7,199
18,274
16,625
Other segment items
53
32,127
4,355
15,106
Net income
75,431
32,488
22,486
50,865
Depreciation and impairment of long-lived assets
-
-
1,490
-
Depreciation
7
-13
-
7
Intangible amortization
5,961
5,961
5,962
5,961
Acquired in-process research & development (ipr&d) expense
0
32,000
4,250
15,000
Stock-based compensation
9,335
10,620
9,972
10,969
Stock appreciation rights market adjustment
241
-312
320
-145
Debt issuance costs amortization
147
151
157
161
Deferred taxes
-3,203
-3,863
7,376
-3,881
Amortization of premiums and accretion of discounts on investment securities
418
220
281
336
Other non-cash expenses
679
560
402
-9
Trade receivables
2,773
11,435
-3,864
7,670
Inventory
1,079
-76
-1,525
782
Prepaid expenses and other assets
7,848
2,996
-24,845
-12,528
Trade payables
-6,916
10,907
-8,648
-1,960
Other liabilities
22,868
-46,184
52,451
28,026
Net cash provided by operating activities
92,432
27,760
126,151
108,734
Purchase of investment securities
152,534
178,995
18,838
24,281
Proceeds from maturities and sales of investment securities
21,031
27,349
20,562
19,563
Purchase of property and equipment
-
-
107
71
Payment of milestones
-
-
19,250
-
Payment of upfront fee related to license agreements
0
32,000
0
0
Net cash used in investing activities
-131,503
-183,646
-17,633
-4,789
Principal repayment of long-term debt
5,000
5,000
5,000
3,750
Payments of employee withholding taxes related to stock-based awards
1,075
2,565
663
0
Proceeds from exercised options
5,517
347
2,648
754
Net cash used in financing activities
-558
-7,218
-3,015
-2,996
Net (decrease) increase in cash, cash equivalents, and restricted cash
-39,629
-163,104
105,503
100,949
Cash, cash equivalents, and restricted cash-beginning of period
589,668
752,772
647,269
453,271
Cash, cash equivalents, and restricted cash-end of period
550,039
589,668
752,772
647,269
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net product revenue
$261,280K
(-32.17%↓ Y/Y)
Interest income
$7,072K
(168.39%↑ Y/Y)
Net income
$75,431K
(-11.61%↓ Y/Y)
Other liabilities
$22,868K
(283.19%↑ Y/Y)
Canceled cashflow
$192,921K
Stock-based compensation
$9,335K
(-61.03%↓ Y/Y)
Intangible amortization
$5,961K
(-50.00%↓ Y/Y)
Other non-cash
expenses
$679K
(-27.15%↓ Y/Y)
Stock appreciation
rights market...
$241K
(319.09%↑ Y/Y)
Debt issuance costs
amortization
$147K
(-55.32%↓ Y/Y)
Depreciation
$7K
(-46.15%↓ Y/Y)
Net cash provided by
operating activities
$92,432K
(-18.43%↓ Y/Y)
Canceled cashflow
$22,237K
Cost of product sold
$63,191K
(-9.90%↓ Y/Y)
Research and development
$44,034K
(-32.55%↓ Y/Y)
Sales and marketing
$32,311K
(-42.70%↓ Y/Y)
Income tax expense
$17,834K
(-16.97%↓ Y/Y)
General and
administrative
$16,884K
(-55.81%↓ Y/Y)
Stock-based compensation
$9,576K
(-59.84%↓ Y/Y)
Depreciation and
amortization
$5,968K
(-50.00%↓ Y/Y)
Interest expense
$3,070K
(-58.97%↓ Y/Y)
Other segment items
$53K
(-99.66%↓ Y/Y)
Net (decrease)
increase in cash, cash...
-$39,629K
(-142.59%↓ Y/Y)
Canceled cashflow
$92,432K
Proceeds from maturities
and sales of...
$21,031K
(-48.63%↓ Y/Y)
Proceeds from exercised
options
$5,517K
(-18.90%↓ Y/Y)
Prepaid expenses and
other assets
$7,848K
(40.49%↑ Y/Y)
Trade payables
-$6,916K
(-147.51%↓ Y/Y)
Deferred taxes
-$3,203K
(70.33%↑ Y/Y)
Trade receivables
$2,773K
(-72.13%↓ Y/Y)
Inventory
$1,079K
(198.27%↑ Y/Y)
Amortization of premiums and
accretion of discounts on...
$418K
(-53.76%↓ Y/Y)
Net cash used in
investing activities
-$131,503K
(-663.35%↓ Y/Y)
Canceled cashflow
$21,031K
Net cash used in
financing activities
-$558K
(81.63%↑ Y/Y)
Canceled cashflow
$5,517K
Purchase of investment
securities
$152,534K
(254.47%↑ Y/Y)
Principal repayment of
long-term debt
$5,000K
(-33.33%↓ Y/Y)
Payments of employee
withholding taxes related to...
$1,075K
(-54.08%↓ Y/Y)
Buy us a coffee